Subscribe
shutterstock_1899198520_t_schneider
T. Schneider / Shutterstock.com
9 November 2021MedtechAlex Baldwin

Qiagen and BD settle PCR lawsuit for £53m

Qiagen will pay Becton, Dickinson (BD) $53 million to settle an ongoing patent infringement lawsuit over polymerase chain reaction (PCR) diagnostics patents.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Jury rules Qiagen infringed two gene patents
31 August 2021   A US District Court for the District of Delaware jury found that German genetics company Qiagen willfully infringed two patents owned by ArcherDX and Massachusetts General Hospital.
Americas
Oxford Immunotec settles with Qiagen, signs $27.5m licence
18 December 2017   UK-based diagnostics company Oxford Immunotec has settled a patent infringement dispute with Qiagen, a provider of sample and assay technologies for molecular diagnostics.
Big Pharma
Qiagen seeks judgment in COVID-19 wastewater testing suit
7 April 2022   Qiagen has asked a Delaware court to issue a declaratory judgment that its method for testing for COVID-19 in wastewater does not infringe Bio-Rad’s patents.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

More on this story

Big Pharma
Qiagen seeks judgment in COVID-19 wastewater testing suit
7 April 2022   Qiagen has asked a Delaware court to issue a declaratory judgment that its method for testing for COVID-19 in wastewater does not infringe Bio-Rad’s patents.
Americas
Jury rules Qiagen infringed two gene patents
31 August 2021   A US District Court for the District of Delaware jury found that German genetics company Qiagen willfully infringed two patents owned by ArcherDX and Massachusetts General Hospital.
Americas
Oxford Immunotec settles with Qiagen, signs $27.5m licence
18 December 2017   UK-based diagnostics company Oxford Immunotec has settled a patent infringement dispute with Qiagen, a provider of sample and assay technologies for molecular diagnostics.

More on this story

Big Pharma
Qiagen seeks judgment in COVID-19 wastewater testing suit
7 April 2022   Qiagen has asked a Delaware court to issue a declaratory judgment that its method for testing for COVID-19 in wastewater does not infringe Bio-Rad’s patents.
Americas
Jury rules Qiagen infringed two gene patents
31 August 2021   A US District Court for the District of Delaware jury found that German genetics company Qiagen willfully infringed two patents owned by ArcherDX and Massachusetts General Hospital.
Americas
Oxford Immunotec settles with Qiagen, signs $27.5m licence
18 December 2017   UK-based diagnostics company Oxford Immunotec has settled a patent infringement dispute with Qiagen, a provider of sample and assay technologies for molecular diagnostics.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent